Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

202,001 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.
Lee KH, Cho BC, Ahn MJ, Lee YG, Lee Y, Lee JS, Kim JH, Min YJ, Lee GW, Lee SS, Lee KH, Ko YH, Shim BY, Kim SW, Shin SW, Choi JH, Kim DW, Cho EK, Park KU, Kim JS, Chun SH, Wang J, Choi S, Kang JH. Lee KH, et al. Among authors: wang j. Cancer Res Treat. 2024 Jan;56(1):48-60. doi: 10.4143/crt.2023.453. Epub 2023 Jun 27. Cancer Res Treat. 2024. PMID: 37402411 Free PMC article. Clinical Trial.
Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer.
Huh KY, Lim Y, Yoon DY, Hwang JG, Sim S, Kang J, Wang J, Kim M, Jang SB, Shreeve SM, Mehta J, Haddish-Berhane N, Oh J, Lee S, Yu KS. Huh KY, et al. Among authors: wang j. Lung Cancer. 2023 Jan;175:112-120. doi: 10.1016/j.lungcan.2022.11.021. Epub 2022 Dec 2. Lung Cancer. 2023. PMID: 36495784 Free article. Clinical Trial.
202,001 results
You have reached the last available page of results. Please see the User Guide for more information.